Adaptive Biotechnologies (NASDAQ:ADPT) Trading Down 4.8% - Here's Why

Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report)'s share price dropped 4.8% during trading on Wednesday . The company traded as low as $4.99 and last traded at $5.00. Approximately 378,947 shares were traded during trading, a decline of 74% from the average daily volume of 1,457,789 shares. The stock had previously closed at $5.25.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ADPT shares. BTIG Research lifted their target price on Adaptive Biotechnologies from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday, October 2nd. JPMorgan Chase & Co. boosted their price target on Adaptive Biotechnologies from $5.00 to $6.00 and gave the company an "overweight" rating in a research note on Friday, August 2nd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $7.00.

Adaptive Biotechnologies Stock Down 4.8 %

The company has a market capitalization of $736.84 million, a PE ratio of -3.36 and a beta of 1.44. The firm's 50-day moving average is $4.62 and its 200-day moving average is $3.80.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.02. Adaptive Biotechnologies had a negative return on equity of 60.99% and a negative net margin of 126.49%. The firm had revenue of $43.19 million during the quarter, compared to analyst estimates of $38.63 million. During the same quarter in the prior year, the company earned ($0.33) EPS. The business's revenue was down 11.7% compared to the same quarter last year. As a group, equities research analysts predict that Adaptive Biotechnologies Co. will post -1.19 EPS for the current year.

Institutional Investors Weigh In On Adaptive Biotechnologies

Large investors have recently made changes to their positions in the company. Personal CFO Solutions LLC purchased a new position in Adaptive Biotechnologies during the 4th quarter valued at about $55,000. Avenir Corp increased its holdings in Adaptive Biotechnologies by 117.1% in the 4th quarter. Avenir Corp now owns 66,365 shares of the company's stock worth $325,000 after acquiring an additional 35,800 shares in the last quarter. Braidwell LP raised its position in shares of Adaptive Biotechnologies by 40.3% during the 4th quarter. Braidwell LP now owns 1,357,490 shares of the company's stock worth $6,652,000 after purchasing an additional 389,800 shares during the last quarter. Clear Street Markets LLC acquired a new position in shares of Adaptive Biotechnologies during the fourth quarter valued at approximately $100,000. Finally, First Trust Direct Indexing L.P. purchased a new position in Adaptive Biotechnologies in the 1st quarter valued at $47,000. 99.17% of the stock is owned by institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.